Dr. Hébert-Magee is a minority health strategist, Louisiana Regional Medical Director, and Associate Professor of Pathology at the University of Central Florida College of Medicine. She was previously an Assistant Professor and Associate Scientist at the University of Alabama at Birmingham Comprehesive Cancer Center. Dr. Hébert-Magee is a reputed cytopathologist with advanced training in translational pathology from the National Cancer Institute. Dr. Hébert-Magee’s primary areas of clinical interests are pancreatic, biliary, and breast neoplasia with an emphasis on cytopathologic interpretation and clinical effectiveness. She has pioneered the application of cytopathologic techniques to innovative diagnostic modalities to improve the diagnosis of pancreatic and biliary cancer. Dr. Hébert-Magee has published over 60 peer reviewed manuscripts, chapters, editorials, and white papers which have led to lectern invitations to Asia, Europe, and South America. Recognizing clinical effectiveness research only improves the diagnostic accuracy and treatment of pancreatic cancer, in 2015, Dr. Hébert-Magee began focusing on the preventive measures of GI tumors in vulnerable and underserved populations. As the founder of UTS, she has served as the executive director for the last five years. She has been the recipient of several honors, awards, and grants, particularly for her research in minority health and health disparities. Dr. Hébert-Magee is graduate of Georgetown University School of Medicine and Harvard T.H. Chan School of Public Health.